Turn Therapeutics Inc. (TTRX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on dermatological diseases, primarily developing GX-03 for moderate-to-severe atopic dermatitis and onychomycosis. The company completed a direct listing on Nasdaq in October 2025 and operates as a single reporting segment. As of March 31, 2026, the company had 29,788,040 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(970,972) | $(328,547) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.01) |
| Cash and Cash Equivalents (End of Period) | $11,217,671 | $1,572,633 |
| Working Capital | $6,322,320 | N/A |
| Total Debt (Long-term, net) | $5,936,514 | $0 |
| Derivative Liabilities | $2,767,462 | $0 |
| Accumulated Deficit | $(23,361,065) | $(19,524,560) |
Note: Working Capital calculated as Total Current Assets ($11.45M) minus Total Current Liabilities ($5.13M).
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $861,146 (224%) to $1.25 million. General and Administrative (G&A) expenses rose by $760,971, driven by increased stock-based compensation ($200k), legal/advisory fees ($360k), and compensation costs ($190k). R&D expenses increased by $100,175 due to Phase 2 clinical trial activities.
- Financing Activity: The company secured a new $25 million credit facility with Avenue Capital, drawing $7.0 million in Tranche 1 during the quarter. This significantly boosted cash reserves compared to the prior year.
- Non-Cash Items: A net gain of $697,561 was recorded from the change in fair value of derivative liability instruments (warrants and put options), partially offsetting the operating loss. Amortization of deferred offering costs increased by $477,647.
- Debt: Long-term debt increased from $0 to $5.94 million (net of discounts) following the Avenue Capital loan agreement.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that cash on hand ($11.2 million) is sufficient to fund operations into the first quarter of 2027. However, the filing explicitly raises substantial doubt about the company's ability to continue as a going concern beyond 12 months without additional financing.
- Capital Requirements: The company estimates it will require $60–$65 million to complete planned Phase 3 trials for atopic dermatitis and onychomycosis, plus $1.5–$2.5 million for its vaccine program.
- Clinical Milestones: Topline results for the GX-03 Phase 2 study in atopic dermatitis are expected in mid-2026. Tranche 2 of the Avenue Capital loan ($8 million) is contingent on dosing first patients in a Phase 3 onychomycosis trial and raising $10 million in equity.
- Risks: Key risks include the inability to raise additional capital, failure of clinical trials, and the high cost of development. The company has no product revenue and relies entirely on financing and licensing deals.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2027" burn rate estimate given the substantial doubt disclosure.
- Debt Covenants: Review the specific milestones required to unlock Tranche 2 ($8M) and Tranche 3 ($10M) of the Avenue Capital loan to assess refinancing risk.
- Derivative Liabilities: Monitor the fair value of the $2.77 million derivative liability, as fluctuations in stock price will directly impact net income/loss.
- Clinical Data: Await the mid-2026 topline data for the GX-03 Phase 2 trial, which is critical for future funding and valuation.
- Share Dilution: Assess the impact of the GEM Share Purchase Agreement (up to $85M available) and the Avenue Capital equity kicker (8% of loan amounts) on future share count.